Clover, Dynavax COVID vaccine trial helps reduce virus transmission in families

Close-up of consecutive Covid-19 coronavirus vaccine vials

MarsBars/E+ via Getty Images

Clover biopharmaceuticals report Additional data published in Clinical infectious disease from phase 2/3 of the SCB-2019 vaccine (CpG 1018/Alum) reduced the risk of SARS-CoV-2 infection to family members compared with participants receiving placebo.

the company has previously reported data from two research groups, named SPECTRA, in August.

Clover said data shows that a household contact is 84 percent less likely to get COVID when an infected member has had SCB-2019, compared with homes where the infected person is not vaccinated.

Of the 134 household contacts of infected family members who received SCB-2019, there was one case of COVID-19; Of the 250 household contacts of infected but unvaccinated family members, 12 have cases, the company added.

Clover noted that there were no cases of COVID symptoms among the partially or fully vaccinated household contacts and the infected member received the SCB-2019 vaccine.

The trial was conducted at eight sites in the Philippines. A total of 154 people who took placebo or SCB-2019 and subsequently became infected with SARS-CoV-2 were enrolled in the study as were 388 family contacts.

Clover created a COVID vaccine by combining SCB-2019 with Dynavax’s (NASDAQ:DVAX) Enhancement excipients CpG 1018 and aluminum hydroxide (alum).

Clover said it is working to complete regulatory submissions in China, the EU and the World Health Organization for SCB-2019 by the end of 2022, and prepare for commercialization.


News7F: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button